Floatz logo

Irinotecan

Duodenum Cancer

University of Southern CaliforniaSmall moleculePhase 1Dormant
CC
47/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
32/ 100
Competitive Position
95/ 100

Competitive context

5 Active assets in the Duodenum Cancer cohort.

Asset / SponsorPhaseRating
N-BUTYL CYANOACRYLATE
Minia University
Phase 3B
Rivaroxaban
Asan Medical Center
Phase 2CCC
Cyclophosphamide
National Cancer Institute (NCI)
Phase 2CCC
Fludarabine
National Cancer Institute (NCI)
Phase 2CCC
Kras Tcr-Transduced Pbl
National Cancer Institute (NCI)
Phase 2CCC

View all 9 →

Same molecule, other indications

Irinotecan is also rated in:

rectal cancerDormant
BBB
Indicative ·
78 / 100
View asset →
exocrine pancreatic carcinomaDormant
BBB
Indicative ·
78 / 100
View asset →
Peritoneal NeoplasmsDormant
BBB
Indicative ·
78 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →